antiviral and associated therapy - versus placebo - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.28 [0.07, 1.04]< 137%5 studies (5/-)97.1 %some concernnot evaluable moderatecrucial-
deaths 0.80 [0.55, 1.16]< 10%12 studies (12/-)88.0 %lowlow highcrucial-
deaths (time to event analysis only) 0.80 [0.43, 1.50]< 10%1 study (1/-)75.7 %NAnot evaluable crucial-
hospitalization or death 0.50 [0.30, 0.84]< 176%8 studies (8/-)99.5 %lownot evaluable highcrucial-
clinical deterioration 0.84 [0.67, 1.05]< 143%6 studies (6/-)93.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.08 [0.99, 1.18]> 10%3 studies (3/-)95.7 %lownot evaluable highimportant-
clinical improvement (14-day) 1.12 [0.85, 1.47]> 113%2 studies (2/-)78.5 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %NAnot evaluable important-
clinical improvement (28-day) 1.07 [0.97, 1.18]> 10%1 study (1/-)91.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.07 [0.98, 1.17]> 10%2 studies (2/-)93.1 %lownot evaluable highimportant-
hospitalization 0.72 [0.62, 0.85]< 10%12 studies (12/-)100.0 %some concernlow moderateimportant-
mechanical ventilation 1.33 [0.56, 3.15]< 10%2 studies (2/-)26.1 %some concernnot evaluable moderateimportant-
Recovery (time to event analysis only) 1.02 [0.92, 1.13]> 10%1 study (1/-)64.7 %NAnot evaluable important-
viral clearance 0.90 [0.78, 1.04]> 127%7 studies (7/-)8.2 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.85 [0.70, 1.02]> 122%4 studies (4/-)4.1 %some concernnot evaluable moderateimportant-
viral clearance by day 7 0.92 [0.73, 1.16]> 129%7 studies (7/-)23.9 %lownot evaluable highimportant-
emergency room observation for > 6 hours or hospitalization 0.64 [0.47, 0.87]< 10%1 study (1/-)99.8 %NAnot evaluable non important-
ICU admission 0.84 [0.43, 1.63]< 10%1 study (1/-)69.8 %NAnot evaluable non important-
recovery 0.96 [0.86, 1.07]> 10%1 study (1/-)23.2 %NAnot evaluable non important-

safety endpoints 00

AE leading to drug discontinuation 0.79 [0.37, 1.69]< 160%4 studies (4/-)72.9 %some concernnot evaluable moderateimportant-
related AE (TRAE) 1.76 [1.10, 2.82]< 10%1 study (1/-)1.0 %NAnot evaluable important-
related SAE (TRSAE) 1.01 [0.25, 4.05]< 10%1 study (1/-)49.6 %NAnot evaluable important-
serious adverse events 0.53 [0.29, 0.98]< 127%5 studies (5/-)97.9 %lownot evaluable highimportant-
adverse events 0.89 [0.75, 1.06]< 10%6 studies (6/-)89.7 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.